Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q86TM3 (cage)
 29,987 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Since 1975 oral 8-methoxypsoralen administered in association with ultraviolet-A radiation (UVA), (PUVA) has been widely used to treat psoriasis and other cutaneous diseases. PUVA is mutagenic, and in animals carcinogenic. Prospective study of a cohort of patients with psoriasis who were first treated with PUVA in 1975-1976 has provided data on the carcinogenic risk of this treatment. There is a dose-dependent increase in the risk of squamous cell cancer of the skin associated with exposure to PUVA. A recent large-scale Swedish study confirmed this association. The risk of squamous cell cancer of the genitals of males exposed to high doses of PUVA is especially high. A consistent, confirmed, and significant relationship of exposure to PUVA to other types of malignancies in man has not been established. Although highly effective in the treatment of psoriasis, the risk of squamous cell cancer associated with long-term therapy with PUVA must be considered in determining when this therapy is appropriate for an individual patient. Additional study of PUVA-treated patients will better define the full spectrum of the carcinogenic risk of PUVA therapy and the clinical behavior of tumors that arise in association with this treatment.
 ...
PMID:Risks of cancer associated with long-term exposure to PUVA in humans: current status--1991. 161 96

Colorectal strictures, either benign or malignant, are not uncommon in ulcerative colitis. Fifty nine of 1156 ulcerative colitis patients (5%) admitted to this hospital between 1959 and 1983 developed 70 separate colorectal strictures. Seventeen of the 70 strictures (24%) proved to be malignant and the other 53 benign. Nine patients developed more than one stricture. Three principal features distinguished the 17 malignant from the 53 benign strictures in this series: (1) appearance late in the course of ulcerative colitis (61% probability of malignancy in strictures that develop after 20 years of disease v 0% probability in those occurring before 10 years); (2) location proximal to the splenic flexure (86% probability of malignancy v 47% in sigmoid, 10% in rectum, and 0% in splenic flexure and descending colon); and (3) symptomatic large bowel obstruction (100% probability of malignancy v only 14% in the absence of obstruction or constipation). Moreover, cancer associated with strictures tends to be more advanced (76% stage D, 24% A and B) than that which does not produce strictures (18% stage D, 59% A and B).
 ...
PMID:Benign and malignant colorectal strictures in ulcerative colitis. 164 33

We have demonstrated that S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR2721) administered to mice 30 min prior to a relatively low dose of ionizing radiation is effective in protecting against radiation-induced carcinogenesis and subsequent life shortening. Female C57BL/6JANL x BALB/cJANL F1 mice, 200 per group, were exposed to gamma radiation at a dose of 206 cGy. Additional groups of 200 animals were sham treated, given injections of 400 mg/kg of WR2721, or administered WR2721 and the irradiated with 60Co photons at doses of 206 cGy or 417 cGy. Mice were treated at 110 days of age. They were housed five to a cage and were checked daily throughout life. All deceased animals were necropsied, and tissues were removed and fixed for histopathological analysis. Over 90% of the animal deaths were due to tumor involvement. WR2721 afforded significant protection (P = 0.0016) against radiation-induced malignancies (i.e., a total of 164 tumor codes were used) following a dose of 206 cGy. Protection against lymphoreticular tumors in particular was significant (P = 0.0165). Subsequent survival time in WR2721-protected animals (compared with matched irradiated controls) was extended by 65 days. Mice irradiated with 417 cGy following administration of WR2721 exhibited a response similar to those irradiated without the protector at a dose of 206 cGy (P = 0.26). Cumulative survival curves for unirradiated mice were unaffected by a single dose of WR2721. These data indicate a potential novel benefit for radioprotectors in cancer therapy. WR2721 and similar aminothiols may be effective adjuvants for reducing the risk of therapy-induced secondary cancers in patients who have an excellent prognosis for cure and long-term survival.
Cancer Res 1991 Aug 15
PMID:Protection against late effects of radiation by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. 165 Nov 55

Our laboratory has developed nuclear magnetic resonance (NMR) techniques for detecting cancer. Using water-suppressed proton (H-1) NMR spectroscopy, we observed that the linewidths of the resonances of methyl and methylene moieties in lipoprotein lipids were consistently narrower in plasma samples from cancer patients than in those from controls. These findings have been corroborated by a number of independent laboratories, but other investigators have been unable to reproduce our results. One reason for the variability of results obtained with H-1 NMR may be that hypertriglyceridemia also induces linewidth narrowing of lipoprotein lipid methyl and methylene resonances, and can cause false positive results. We show that this ambiguity can be circumvented by using a second test based on the carbon-13 (C-13) NMR spectrum of plasma. Here we postulate that the cancer-associated changes seen in H-1 and C-13 NMR spectra are caused by peroxidation of lipoprotein lipids, an effect that may be induced by tumor necrosis factor-alpha released during malignancy.
Cancer Cells 1991 May
PMID:The NMR blood test for cancer: current status. 165 67

Radiolabeled antibodies are gaining in application for the imaging and therapy of cancers. Much progress has been made in the use of these new biological reagents for tumors of the gastrointestinal system, and the current status, problems and prospects are reviewed in this paper. It is apparent that murine monoclonal antibodies against cancer-associated antigens are safe and useful for revealing a high percentage of sites of tumor, including some missed by conventional radiological methods. Tumors as small as 0.5 cm can be disclosed, even in organs that are difficult for CT scan interpretation. Major advances in cancer imaging have involved the use of antibody fragments and simple, direct labeling methods for 99mTc, the most widely used radionuclide in nuclear medicine. The use of radiolabeled antibodies for cancer therapy has been a more difficult endeavor, particularly because of the delivery of inadequate rad doses to tumor. Advances include humanization of monoclonal antibodies and the improved attachment of therapeutic radionuclides, such as 90Y and 186Re or 188Re.
 ...
PMID:Imaging and therapy of gastrointestinal cancers with radiolabeled antibodies. 165 26

Albino rats and mice are sensitive to light and the recommended illumination of animal rooms (75-125 ft-candles) is known to cause retinal damage. When a room is illuminated by ceiling lights, animals in the cages of the top row and, to some extent, in the side columns of cage racks will be exposed to higher light intensity than those in the other cages of the rack. In 2-yr chemical carcinogenicity studies of the National Toxicology Program (previously the Carcinogenicity Bioassay Program of the National Cancer Institute), Fischer 344 rats were group-housed in hanging drawer-type clear polycarbonate cages. During the course of the chronic studies, a number of rats developed opacity of the eye. Ocular examination indicated chronic uveitis, deep interstitial keratitis, cataract formation leading to panophthalmitis, and in severe cases, phthisis bulbi. Histologic examination showed cataract and retinal degeneration. Incidences of these lesions were highest (greater than 55%) in the rats of the top rows and lowest in those of the bottom rows (less than 10%) of cages with no relation to chemical treatment, indicating an association with light intensity. The incidence of these eye lesions was markedly decreased (less than 15%) by decreasing the light intensity of the animal room to less than 50 ft-candles at 5 ft from the floor and rotating the cages in each column of a rack from top to bottom when cages or racks were changed.
 ...
PMID:Light intensity-associated eye lesions of Fischer 344 rats in long-term studies. 166 69

Pamidronate [aminohydroxypropylidene diphosphonate disodium (APD), disodium pamidronate] is an orally and intravenously active amino-substituted bisphosphonate which produces potent and specific inhibition of bone resorption at doses devoid of any significant detrimental effect on bone growth and mineralisation. Clinical trials indicate that pamidronate is effective in a variety of conditions characterised by pathologically enhanced bone turnover, including Paget's disease, hypercalcaemia of malignancy, osteolytic bone metastasis, steroid-induced osteoporosis and idiopathic osteoporosis. Pamidronate is highly effective in restoring normocalcaemia in patients with hypercalcaemia of malignancy associated with bone metastases but, in common with other bisphosphonates, is marginally less effective against humoral hypercalcaemia of malignancy. Comparative studies in this area have suggested that, at therapeutic doses, pamidronate has a more pronounced calcium-lowering action than etidronate (etidronic acid) and clodronate (clodronic acid) and provides a longer period of normocalcaemic remission. In Paget's disease arrest and, in some patients, reversal of the progression of osteolytic lesions by pamidronate is associated with a sustained reduction in bone pain, improved mobility and a possible reduced risk of bone fracture. In patients with osteolytic bone metastasis pamidronate reduces skeletal morbidity and slows the progression of metastatic bone destruction. Long term use of low-dose pamidronate in conjunction with conventional antiosteoporotic therapy may halt bone loss in steroid-induced and idiopathic osteoporosis. Pamidronate appears to represent a valuable addition to the drugs currently available for the treatment of symptomatic Paget's disease and cancer-associated hypercalcaemia, and shows promise in the treatment of osteolytic bone metastasis and osteoporosis.
 ...
PMID:Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. 170 54

The physicochemical properties, pharmacology, pharmacokinetics, serum concentrations and clinical effects, adverse effects and contraindications, and dosage of transdermally administered fentanyl are described, and clinical studies evaluating the use of a transdermal fentanyl system in the treatment of postoperative pain and chronic cancer-associated pain are reviewed. After application of a transdermal system, fentanyl is absorbed into the skin beneath the patch, where a depot forms in the upper skin layers. Plasma fentanyl concentrations are barely detectable for about two hours after patch placement. Eight to 12 hours after patch placement, concentrations approximate those achieved with equivalent i.v. doses of fentanyl. Some studies comparing transdermally administered fentanyl with placebo in postoperative patients showed that the patients who received fentanyl required fewer supplementary analgesics and reported less pain than the patients who received placebo. However, the overall efficacy and safety of the transdermal fentanyl system for the treatment of postoperative pain have not been adequately evaluated. Studies of cancer patients showed that transdermally administered fentanyl appears to be effective in the management of chronic, cancer-related pain. Dermatological reactions to the fentanyl patch are generally transient and mild. Other adverse effects are those that are commonly associated with narcotic analgesics. The 25-micrograms/hr patch should be used for initial treatment in patients not previously treated with narcotics. The dosage may be gradually increased until effective analgesia is obtained. Although experience with the product is limited, transdermally administered fentanyl appears to be effective for the long-term management of cancer-related pain.
 ...
PMID:Transdermally administered fentanyl for pain management. 825 54

A novel method has been developed to quantify alpha(1----3)-L-fucosyltransferase activity in human sera by applying a sandwich-type immunoradiometric assay. H type 2 trisaccharide (6Fuc alpha 1----2Gal beta 1----4GlcNAc) covalently attached to bovine serum albumin (BSA) was used as an acceptor and incubated with serum samples in the presence of guanosine diphosphate-fucose. The resulting product, Y tetrasaccharide (Fuc alpha 1----2Gal beta 1----4[Fuc alpha 1----3] GlcNAc beta-BSA), was detected by a sequential use of anti-BSA antibody-coated bead and 125I-labeled anti-Y antibody. Inter- and intra-assay CVs for alpha(1----3)-L-fucosyltransferase were both less than 4%, and the results of the dilution linearity and analytical recovery studies were satisfactory. Using the present assay method, we measured alpha(1----3)-L-fucosyltransferase in serum from patients with benign and malignant gastric disorders and in healthy subjects. The detection rate of alpha(1----3)-L-fucosyltransferase for cancer was apparently higher than that of carcinoembryonic antigen measured in the same samples, particularly in the early clinical stage; indeed, no correlation was observed between the concentrations of the two potential markers. The results indicate that the present assay method seems to be excellent for the determination of serum alpha(1----3)-L-fucosyltransferase activity and useful for the detection of cancer-associated increases of the enzyme activity at the early stage of gastric cancer.
 ...
PMID:Novel method for quantifying alpha(1----3)-L-fucosyltransferase activity in serum. 176 83

The cancer stroma is made of cellular and non cellular formations which grow along with cancer cells to build up a tumor. It comes from inflammatory cells and mesenchymal tissue which are mobilized and modified by factors released by cancer cells which bring about inflammatory cell accumulation, angiogenesis, fibroblast mitosis and extracellular matrix production. The extracellular matrix is altogether a barrier against and supporting to cancer cells. The extracellular matrix is also involved in the storage of growth factors which are bound to glycosaminoglycans. Although they are antinomic in vitro, peptidic factors released by tumor cells seem to have an enhancing effect on tumor growth in vivo. The cancer invasion is mediated through diverse enzyme activities, particularly proteases, which degrade the matrix whose degradation products can facilitate the tumor progression. The anti-cancer activity which is exhibited in vitro by macrophages and lymphocytes is expressed at a low level by tumor-macrophages and lymphocytes in vivo. The cancer associated inflammation has no particular feature which could help to screening or to follow up patients. Several elements of the cancer stroma could be selected as targets for investigative cancer therapy.
Bull Cancer 1991
PMID:[Cancer stroma]. 176 34


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>